Nataraj Kalyanaraman, VP & Head of Drug Development, Hyderabad, Bristol Myers Squibb

Speaker in this video:
Nataraj Kalyanaraman, VP & Head of Drug Development, Hyderabad, Bristol Myers Squibb

Topic: From Cost Centers to Innovation Engines: The Evolving Role of GCCs in Pharma R&D

Key Highlights:
[1] GCC are moving from being support generators to becoming strategic powerhouses driving innovation and drug development.

[2] ⁠The industry faces a higher regulatory bar, increasing competition, and macroeconomic pressures, making GCCs more critical for accelerating R&D productivity.

[3] India is transforming into the “Pharmacy of the World,” playing a central role in drug development and clinical research for global pharma companies.

[4] The Hyderabad center serves as an integrated global hub focusing on innovative solutions, diverse talent development, and helping patients with serious diseases.

[5] ⁠Emphasis on fostering collaboration, deepening global integration, and building future-ready talent to strengthen pharma R&D capabilities.